Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Sangamo Therapeutics Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, indicating a varied technical focus within the life sciences sector. The prosecution involves 4 distinct examiners, meaning each pending action is being handled by a different individual. This distribution requires a strategy that addresses the specific scientific expertise of each reviewer.
RYAN, DOUGLAS CHARLES is the busiest examiner for the portfolio, with 1 pending office action currently assigned. The presence of the active matters across 3 distinct art units suggests that the company is navigating multiple examination frameworks simultaneously. Practitioners should note that the 4 distinct examiners provide a broad range of feedback that may influence the overall strategy for the Biotechnology & Pharmaceuticals portfolio. Maintaining consistency across these different administrative divisions is essential for long term success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.7% | +57.4% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | — |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | — |
| 18247093 | NOVEL ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING ALPHA-SYNUCLEIN EXPRESSION | MARTINEZ, TARA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | — |
| 18493366 | ENGINEERED TARGET SPECIFIC NUCLEASES | CHOWDHURY, IQBAL HOSSAIN | — |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | — |
| 18247093 | NOVEL ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING ALPHA-SYNUCLEIN EXPRESSION | MARTINEZ, TARA L | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1633 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | RYAN, DOUGLAS CHARLES | — | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18493366 | ENGINEERED TARGET SPECIFIC NUCLEASES | CHOWDHURY, IQBAL HOSSAIN | 1656 | §112 | Final Rejection | — | Pending | Oct 24, 2023 |
| 18249418 | GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS | WESTON, ALYSSA G | 1633 | §102§103§112 | Final Rejection | — | Pending | Apr 18, 2023 |
| 18247093 | NOVEL ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING ALPHA-SYNUCLEIN EXPRESSION | MARTINEZ, TARA L | 1654 | §103§112 | Non-Final OA | — | Pending | Mar 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial